Перейти к содержимому
Bending the Curve Trial by Trial
?EN

Назад: Рак эндометрия

Список литературы: Рак эндометрия

100 источников, процитированных на этой странице. Ссылки ведут к первоисточнику.

  1. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293(23):1164-7. PubMedDOI
    ЦитироватьЗагрузка…
  2. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293(23):1167-70. PubMedDOI
    ЦитироватьЗагрузка…
  3. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294(23):1262-7. PubMedDOI
    ЦитироватьЗагрузка…
  4. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56(4):419-27. PubMed
    ЦитироватьЗагрузка…
  5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. PubMedDOI
    ЦитироватьЗагрузка…
  6. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(8 Suppl):2035-41. PubMedDOI
    ЦитироватьЗагрузка…
  7. Creasman WT, Eddy GL. Recent advances in endometrial cancer. Semin Surg Oncol. 1990;6(6):339-42. PubMedDOI
    ЦитироватьЗагрузка…
  8. Tsukamoto N. [Surgical treatment of endometrial cancer]. Gan No Rinsho. 1990;36(10):1149-54. PubMed
    ЦитироватьЗагрузка…
  9. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275(5):370-5. PubMedDOI
    ЦитироватьЗагрузка…
  10. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44. PubMedDOI
    ЦитироватьЗагрузка…
  11. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404-11. PubMedDOI
    ЦитироватьЗагрузка…
  12. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66. PubMedDOI
    ЦитироватьЗагрузка…
  13. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744-51. PubMedDOI
    ЦитироватьЗагрузка…
  14. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(19):3902-8. PubMedDOI
    ЦитироватьЗагрузка…
  15. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36-44. PubMedDOI
    ЦитироватьЗагрузка…
  16. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16. PubMedDOI
    ЦитироватьЗагрузка…
  17. ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137-46. PubMedDOI
    ЦитироватьЗагрузка…
  18. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-36. PubMedDOI
    ЦитироватьЗагрузка…
  19. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331-6. PubMedDOI
    ЦитироватьЗагрузка…
  20. Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol. 2010;11(8):772-80. PubMedDOI
    ЦитироватьЗагрузка…
  21. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816-23. PubMedDOI
    ЦитироватьЗагрузка…
  22. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165-72. PubMedDOI
    ЦитироватьЗагрузка…
  23. Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12(5):469-76. PubMedDOI
    ЦитироватьЗагрузка…
  24. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631-8. PubMedDOI
    ЦитироватьЗагрузка…
  25. Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, et al. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. J Gynecol Oncol. 2012;23(4):251-6. PubMedDOI
    ЦитироватьЗагрузка…
  26. Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82(3):1249-55. PubMedDOI
    ЦитироватьЗагрузка…
  27. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30(7):695-700. PubMedDOI
    ЦитироватьЗагрузка…
  28. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. PubMedDOI
    ЦитироватьЗагрузка…
  29. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930-6. PubMedDOI
    ЦитироватьЗагрузка…
  30. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299-310. PubMedDOI
    ЦитироватьЗагрузка…
  31. Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, et al. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017;317(12):1224-1233. PubMedDOI
    ЦитироватьЗагрузка…
  32. Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384-392. PubMedDOI
    ЦитироватьЗагрузка…
  33. Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer "types" in the 21st century. Gynecol Oncol. 2017;144(2):243-249. PubMedDOI
    ЦитироватьЗагрузка…
  34. Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802-813. PubMedDOI
    ЦитироватьЗагрузка…
  35. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. PubMedDOI
    ЦитироватьЗагрузка…
  36. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018;36(20):2044-2051. PubMedDOI
    ЦитироватьЗагрузка…
  37. Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018;119(9):1067-1074. PubMedDOI
    ЦитироватьЗагрузка…
  38. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-1285. PubMedDOI
    ЦитироватьЗагрузка…
  39. FDA. Prescribing information, Keytruda (pembrolizumab), revised 09/2019 (BLA 125514/S-065 labeling), section 14.15 Endometrial Carcinoma. Источник
  40. FDA. Accelerated approval letter, BLA 125514/S-065 (Keytruda, pembrolizumab, with lenvatinib for advanced endometrial carcinoma), e-signed 17 September 2019. Источник
  41. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317-2326. PubMedDOI
    ЦитироватьЗагрузка…
  42. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res. 2020;26(15):3928-3935. PubMedDOI
    ЦитироватьЗагрузка…
  43. León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020;38(29):3388-3397. PubMedDOI
    ЦитироватьЗагрузка…
  44. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020;38(26):2981-2992. PubMedDOI
    ЦитироватьЗагрузка…
  45. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841-3850. PubMedDOI
    ЦитироватьЗагрузка…
  46. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020;6(11):1766-1772. PubMedDOI
    ЦитироватьЗагрузка…
  47. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol. 2021;154:327-353. PubMedDOI
    ЦитироватьЗагрузка…
  48. Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, et al. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surg. 2021;156(2):157-164. PubMedDOI
    ЦитироватьЗагрузка…
  49. EMA. Jemperli (dostarlimab): European public assessment report page (opinion adopted 25/02/2021; marketing authorisation issued 21/04/2021), accessed 21 October 2026. Источник
  50. FDA. Accelerated approval letter, BLA 761174 (Jemperli, dostarlimab-gxly), e-signed 22 April 2021. Источник
  51. FDA. Supplement approval and fulfillment of postmarketing requirement letter, BLA 125514/S-105 (Keytruda, pembrolizumab, with lenvatinib), e-signed 21 July 2021. Источник
  52. FDA. Supplement approval letter, BLA 125514/S-110 (Keytruda, pembrolizumab, single agent for MSI-H or dMMR advanced endometrial carcinoma), e-signed 21 March 2022. Источник
  53. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437-448. PubMedDOI
    ЦитироватьЗагрузка…
  54. Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-877. PubMedDOI
    ЦитироватьЗагрузка…
  55. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383-394. PubMedDOI
    ЦитироватьЗагрузка…
  56. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388(23):2159-2170. PubMedDOI
    ЦитироватьЗагрузка…
  57. FDA. Supplement approval letter, BLA 761174/S-003 and S-004 (Jemperli, dostarlimab-gxly monotherapy; regular approval, Subpart E fulfilled), e-signed 9 February 2023. Источник
  58. FDA. Supplement approval letter, BLA 761174/S-006 (Jemperli, dostarlimab-gxly, with carboplatin and paclitaxel for dMMR or MSI-H primary advanced or recurrent endometrial cancer), e-signed 31 July 2023. Источник
  59. Makker V, Colombo N, Casado Herráez A, Monk BJ, Mackay H, Santin AD, et al. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023;41(16):2904-2910. PubMedDOI
    ЦитироватьЗагрузка…
  60. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-2158. PubMedDOI
    ЦитироватьЗагрузка…
  61. Correction to "FIGO staging of endometrial cancer" (correction to Berek JS et al., Int J Gynaecol Obstet 2023;162:383-394). Int J Gynaecol Obstet. 2024;166(3):1374. First published online 6 October 2023. PMID 37803501; DOI 10.1002/ijgo.15193; read on the publisher page 2026-10-31. PubMedDOIИсточник
  62. FDA. Accelerated approval letter, BLA 761139/S-028 (Enhertu, fam-trastuzumab deruxtecan-nxki, HER2-positive (IHC 3+) solid tumors), e-signed 5 April 2024. Источник
  63. FDA. Supplement approval letter, BLA 761069/S-045 (Imfinzi, durvalumab, with carboplatin and paclitaxel for dMMR primary advanced or recurrent endometrial cancer), e-signed 14 June 2024. Источник
  64. FDA. Prescribing information, Jemperli (dostarlimab-gxly) injection, revised 08/2024 (BLA 761174/S-009 labeling). Источник
  65. FDA. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy. FDA notice dated 1 August 2024 (BLA 761174/S-009). Источник
  66. FDA. Supplement approval letter, BLA 125514/S-155 (Keytruda, pembrolizumab, with carboplatin and paclitaxel for primary advanced or recurrent endometrial carcinoma), e-signed 17 June 2024. Источник
  67. Gaffney D, Matias-Guiu X, Mutch D, Scambia G, Creutzberg C, Fotopoulou C, et al. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution. Gynecol Oncol. 2024;184:245-253. PubMedDOI
    ЦитироватьЗагрузка…
  68. Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024;35(8):728-738. PubMedDOI
    ЦитироватьЗагрузка…
  69. Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024;35(11):968-980. PubMedDOI
    ЦитироватьЗагрузка…
  70. Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024;42(3):283-299. PubMedDOI
    ЦитироватьЗагрузка…
  71. Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025. J Natl Compr Canc Netw. 2025;23(8):284-291. PubMedDOI
  72. Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423-e435. PubMedDOI
    ЦитироватьЗагрузка…
  73. EMA. Jemperli: EPAR, procedural steps taken and scientific information after the authorisation (archive), accessed 21 October 2026. Источник
  74. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31(5):1539-1546. PubMedDOI
    ЦитироватьЗагрузка…
  75. FDA. Prescribing information, Jemperli (dostarlimab-gxly), label version effective 2 September 2025 (openFDA drug label record, set ID 095eab9f-545a-4f12-bfb7-19477fb901a5). Источник
  76. FDA. Prescribing information, Lynparza (olaparib) tablets, NDA 208558/S-031 labeling (July 2025). Источник
  77. Koskas M, Crosbie EJ, Fokdal L, McCluggage WG, Mileshkin L, Mutch DG, et al. Cancer of the corpus uteri: A 2025 update. Int J Gynaecol Obstet. 2025;171 Suppl 1(Suppl 1):60-77. PubMedDOI
    ЦитироватьЗагрузка…
  78. Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, et al. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2025;43(9):1055-1060. PubMedDOI
    ЦитироватьЗагрузка…
  79. Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, et al. Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecol Oncol. 2025;192:128-136. PubMedDOI
    ЦитироватьЗагрузка…
  80. Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. Lancet Oncol. 2025;26(10):1370-1381. PubMedDOI
    ЦитироватьЗагрузка…
  81. Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, et al. Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. J Clin Oncol. 2025;43(3):251-259. PubMedDOI
    ЦитироватьЗагрузка…
  82. Cancer Research UK. Uterine cancer survival statistics. Health professional page. Accessed 21 October 2026; the page displays no update date. Источник
  83. ClinicalTrials.gov. NCT00411138 (PORTEC-3). Registry record, accessed 21 October 2026. NCT00411138
  84. ClinicalTrials.gov. NCT03469674 (PORTEC-4a). Registry record, accessed 21 October 2026. NCT03469674
  85. ClinicalTrials.gov. NCT04634877 (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Registry record, accessed 21 October 2026. NCT04634877
  86. ClinicalTrials.gov. NCT05173987 (KEYNOTE-C93). Registry record, API v2, accessed 21 October 2026. NCT05173987
  87. ClinicalTrials.gov. NCT05201547 (DOMENICA). Registry record, API v2, accessed 21 October 2026. NCT05201547
  88. ClinicalTrials.gov. NCT05256225 (NRG-GY026). Registry record, API v2, accessed 21 October 2026. NCT05256225
  89. ClinicalTrials.gov. NCT06132958 (TroFuse-005). Registry record, API v2, accessed 21 October 2026. NCT06132958
  90. ClinicalTrials.gov. NCT06486441 (ASCENT-GYN-01). Registry record, API v2, accessed 21 October 2026. NCT06486441
  91. ClinicalTrials.gov. NCT06989112 (DESTINY-Endometrial01). Registry record, API v2, accessed 21 October 2026. NCT06989112
  92. FDA. Prescribing information, Enhertu (fam-trastuzumab deruxtecan-nxki), label version effective 15 May 2026 (openFDA drug label record, set ID 7e67e73e-ddf4-4e4d-8b50-09d7514910b6). Источник
  93. FDA. Prescribing information, Imfinzi (durvalumab), label version effective 31 August 2026 (openFDA drug label record, set ID 8baba4ea-2855-42fa-9bd9-5a7548d4cec3). Источник
  94. FDA. Prescribing information, Keytruda (pembrolizumab), label version effective 10 July 2026 (openFDA drug label record, set ID 9333c79b-d487-4538-a9f0-71b91a02b287). Источник
  95. Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775. J Immunother Cancer. 2026;14(2). PubMedDOI
    ЦитироватьЗагрузка…
  96. Powell MA, Roed H, Willmott LJ, Cibula D, Black D, Valabrega G, et al. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial. Gynecol Oncol. 2026;212:207-217. PubMedDOI
    ЦитироватьЗагрузка…
  97. Powell MA, Ghamande S, Hanker LC, Black D, Raaschou-Jensen N, Gilbert L, et al. Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy. Int J Gynecol Cancer. 2026;36(8):104774. PubMedDOI
    ЦитироватьЗагрузка…
  98. National Cancer Institute, SEER Program. Site Recode ICD-O-3/WHO 2008 Definition. https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html. Page accessed 20 October 2026. Источник
  99. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Uterine Cancer. Page accessed 21 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Источник
  100. van den Heerik ASVM, Horeweg N, Haverkort MAD, Kuijsters N, Kommoss S, Koppe FLA, et al. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2026;27(1):23-35. PubMedDOI
    ЦитироватьЗагрузка…